Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors.
IMPLANET focuses on spine and knee products.
Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark.
Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation.
Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals.
IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.
IMPLANET focuses on spine and knee products.
Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark.
Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation.
Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals.
IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.
Total raised: $10.68M
Founded date: 2007
Investors 3
| Date | Name | Website |
| 29.01.2021 | M Capital ... | mcapital.f... |
| - | Andera Par... | anderapart... |
| - | Wellington... | wellington... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.04.2010 | - | $10.68M | - |
Mentions in press and media 4
| Date | Title | Description |
| 18.01.2022 | Implanet : Inside Information / Information on annual revenues | IMPLANET announces 2021 revenue growth of 58%, under IFRS Total revenue of €7.7 million, +29% including the divested MADISONTM activity Successful strategic repositioning: strengthening of the Spine business (+62% in 2021) with the acquisit... |
| 01.04.2021 | IMPLANET SA Implanet : Holding of Implanet's AGM on May 5, 2021 at 2 pm CEST | Holding of Implanet's AGM on May 5, 2021 at 2 pm CEST Online voting available Live presentation of the AGM via web conference https://us02web.zoom.us/webinar/register/WN_C64TbhI8S4GjScdgJCiCyA Bordeaux, Boston, March 31, 2021 - 5.45 pm CEST... |
| 19.03.2021 | Implanet : confirms offer to acquire a majority stake in Orthopaedic & Spine Development | Implanet confirms offer to acquire a majority stake in Orthopaedic & Spine Development • Orthopaedic & Spine Development ("OSD") is a manufacturer of implants for spine surgery • Acquisition of a majority interest will lea... |
| 26.04.2010 | Implanet Raises €8M | Implanet S.A., a Bordeaux, France-based Medical Device and Healthcare Information Technology company, raised an additional €8m (US$11m). Investors include CM-CIC Private Equity, which committed €4m, and existing backers Edmond de Rothschild... |